New Technology Kills Tumors With Electric Fields
Posted on August 8, 2007Technology Review reports that an Isreali company called NovoCure is testing a new cancer fighting weapon that uses a weak electric fields to destroy cancer cells. The article says the process has destroyed every type of cancer cell in animal tests. Studies are being done on breast cancer in Europe and on glioblastoma, a deadly brain cancer in the U.S. and Europe. The technology works because cancer cells divide more quickly and have a different shape than normal cells. This feature of cancer cells allows them to be destroyed by the electric field while normal cells survive unscathed.
The electric fields' different effects on normal and dividing cells mostly have to do with geometry. A dividing cell has what Palti calls "an hourglass shape rather than a round shape." The electric field generated by the NovoCure device passes around and through round cells in a uniform fashion. But the narrow neck that pinches in at the center of a dividing cell acts like a lens, concentrating the electric field at this point. This non-uniform electric field wreaks havoc on dividing cells. The electric field tears apart important biological molecules, such as DNA and the structural proteins that pull the chromosomes into place during cell division. Dividing cells simply "disintegrate," says Palti.There is some equipment patients have to carry with them but no one is going to mind having to lug around equipment if it will cure them of their deadly cancer. You can see a video of a presentation by Mike Ambrogi of NovoCure to the Central New Jersey Brain Tumor Support Group here.
Palti, who for years has been studying the effect of electric fields on cancer and normal cells, says that he has verified this mechanism in computer models and experiments in the lab. "The physics are solid," says David Cohen, associate professor of radiology at Harvard Medical School.
Patients in the glioblastoma clinical trial wear the device almost constantly, carrying necessary components in a briefcase. A wire emerging from the briefcase connects to adhesive electrodes covering the skull. Alternating electric fields pass through the scalp, into the skull, and on to the brain. The Food and Drug Administration approved the device for late-stage clinical trials for glioblastoma following promising results from a pilot study in 10 patients, one of whom had a complete recovery.